Outlook Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $143.6M
- Price
- $0.59
- % Change (Daily % change from the live per-ticker quote feed.)
- +3.15%
- Volume
- 4.2M
About
Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions. Its flagship drug candidate, ONS-5010, is an ophthalmic formulation of bevacizumab currently undergoing crucial Phase III clinical trials. This investigational product is being evaluated for its potential to treat wet age-related macular degeneration and other serious retinal diseases. The company has forged strategic collaboration and licensing agreements with several partners, including IPCA Laboratories Limited, Laboratorios Liomont, S.A. de C.V., BioLexis Pte. Ltd., and Zhejiang Huahai Pharmaceutical Co., Ltd. Incorporated in 2010, the firm was formerly known as Oncobiologics, Inc., changing its name to Outlook Therapeutics, Inc. in November 2018. Its corporate base is located in Iselin, New Jersey.
Quick stats
Shares outstanding243.4M
Computed float83.0M
Float / shares34.1%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001649989
AI Summary
AI-generated1/42
minorneutralexecutive change
Outlook Therapeutics Highlights What the Appointment of New CFO Kevin Lundquist Means for the Company’s Next Chapter in Virtual Investor Discussion
Outlook Therapeutics promoted a Virtual Investor segment featuring recently appointed CFO Kevin Lundquist discussing his decision to join the company.
Lundquist framed his arrival as part of the company's transition to a commercial-stage business following FDA approval of LYTENAVA, the only FDA-approved ophthalmic bevacizumab formulation for wet AMD.
No new financial results, guidance, or launch timing were disclosed in the release.